02 Feb 2025 4 min read

BiQ: Weekly Recap for February 2, 2025 (Free)

Welcome to the BiQ Weekly Recap #2!

The week seemed to be going so well, with the XBI forming a double bottom near the 92 level and then running to the 95 level by Friday afternoon. However, confirmation from the Trump Administration that broad new tariffs would go into effect over the weekend abruptly reversed Friday's rally, with the XBI ending the week nearly flat as political headlines continue to drive market volatility.

Since BiQ is not a trading site, my focus remains squarely on the long-term picture while mostly ignoring near-term volatility (unless it is specifically relevant to a particular thesis.) Still, equanimity can be a challenging trait to master. I was reminded of this on Friday while serving Jury Duty.

I checked my portfolio during my first break and saw that it was up by over 4%--which allowed me to happily focus on the Prosecution's arguments for the rest of the morning. When I next checked my portfolio at lunchtime, however, it was down by around 0.1%--what?! I admit that the rest of the afternoon suddenly seemed to go by a lot more slowly.

Talking about equanimity is easy. Practicing it--not so much.

BiQ Service Updates

Reorganized the Main Menu to make it easier for Free, Starter, and Premium Members to quickly access content relevant to their membership status.
The Catalyst Tracker and Events Calendar tools were added.
The Contact Biotech iQ form was added to make it easier for members to contact me directly.
The Biotech iQ Ratings Card, displaying BiQ Buy/Sell/Hold ratings, was added to the Coverage List page.
The Biotech iQ Current & Past Performance page was added to help track the performance of BiQ's past and current portfolio holdings.
Updated the BiQ Events Calendar. Events are now displayed in Members' local time zone. Members can also download events directly to their personal Outlook, Google, or Yahoo calendars by clicking the "Add to Calendar" link in the Event popup.
Added a carousel feature allowing members to quickly scroll through iQ Quick Summaries on the main Cheat Sheets page. Clicking on Summary takes users directly to the iQ Cheat Sheet page for the selected investment.
Added interactive stock charts to each iQ Cheat Sheet page for each investment.

BiQ Coverage List Updates

Posted an iQ Cheat Sheet for RGNX.
Updated the iQ Cheat Sheet for STXS.
Added CGEM to the Watch List.
Added GERN to the Watch List.

BiQ Trades

Become a BiQ Member to see information about BiQ Trades.

Here is the updated BiQ Past Performance table.

BiQ News & Updates

STXS announced MAGiC CE Mark approval in Europe, allowing the company to sell its MAGiC catheters in European markets immediately. This is a significant milestone for the company and should lead to a dramatic improvement in gross margins and allow the company to return to growth over the coming quarters. FDA approval is expected later this year. Click here to read the BiQ update.
STXS also announced the first sale of its next-generation GenesisX robotic platform. GenesisX has been approved in the EU; FDA approval is expected later this year. Click here to read the BiQ update.
CGEM, a BiQ Watch List company, reported positive Phase 2b data for Zipalertinib in patients with NSCLC harboring EGFR Exon 20 insertion mutations. Top-line results will be presented at an international medical conference, and the company plans to submit for US regulatory approval in the second half of 2025. Click here to read the BiQ update.
Several events were added to the BiQ Events Calendar for URGN, CGEM, SWTX, RGNX, and MIST.
EOLS pre-announced unaudited earnings of $79.0M last Tuesday, well above my and Wall Street's expectations (read the BiQ article here.) Shares ran up on the news and finished last week at $14.23.
10 out of the 17 companies on the BiQ 2024 Q4 Revenue Projections Scorecard have already pre-announced Q4 earnings, with seven companies remaining. Except for AVDL and RCEL, earnings continue to be neutral-to-strong for most names on the Scorecard, and the theses continue to progress as per expectations.

BiQ Ratings Card

Become a BiQ Member to view the BiQ Ratings Card and Coverage List.

Become a BiQ Member!

Biotech iQ now offers two paid membership tiers, Starter and Premium. Starter membership is perfect for those who may not be ready to commit to a BiQ Premium membership. Starter Members get access to at least five BiQ-covered stocks, while Premium Members receive access to the complete BiQ Coverage List (currently around 20 stocks) plus coverage on 10-15 Watch List stocks and access to the BiQ Catalyst & Events Calendar. For a limited time, I am offering a 20% discount on Premium memberships with the discounted rate locked in for life. Click here to take advantage of this offer.

Please read more about BiQ Memberships in the About section of this website.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary.